Accelerator leads Rodeo's series A round
Newly launched Rodeo Therapeutics Corp. (Seattle, Wash.) raised $5.9 million in a series A round led by Accelerator Corp. (Seattle, Wash.). Also participating were AbbVie Ventures, Alexandria Venture Investments, ARCH Venture, Eli Lilly and Co. (NYSE:LLY), the Johnson & Johnson Innovation - JJDC Inc. unit of Johnson & Johnson (NYSE:JNJ), Watson Fund, WRF Capital and WuXi AppTec Co. Ltd. (Shanghai, China).
Accelerator VP Alice Chen told BioCentury that Rodeo's lead candidate, an inhibitor of hydroxyprostaglandin dehydrogenase 15 NAD (HPGD; 15-PGDH), could be used to treat a broad range of indications in regeneration and repair. Rodeo will focus initially on inflammatory bowel disease (IBD) and blood cell reconstitution following bone marrow transplant...
BCIQ Company Profiles
BCIQ Target Profiles